AR079050A1 - Compuestos benzoimidazolicos y sus usos - Google Patents
Compuestos benzoimidazolicos y sus usosInfo
- Publication number
- AR079050A1 AR079050A1 ARP100104240A ARP100104240A AR079050A1 AR 079050 A1 AR079050 A1 AR 079050A1 AR P100104240 A ARP100104240 A AR P100104240A AR P100104240 A ARP100104240 A AR P100104240A AR 079050 A1 AR079050 A1 AR 079050A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- benzoimidazolic
- compounds
- salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 10
- 238000000034 method Methods 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- -1 for example Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26226309P | 2009-11-18 | 2009-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079050A1 true AR079050A1 (es) | 2011-12-21 |
Family
ID=44059844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104240A AR079050A1 (es) | 2009-11-18 | 2010-11-17 | Compuestos benzoimidazolicos y sus usos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8530467B2 (https=) |
| EP (1) | EP2501697B1 (https=) |
| JP (1) | JP5657018B2 (https=) |
| KR (1) | KR20120113709A (https=) |
| CN (1) | CN102741245B (https=) |
| AR (1) | AR079050A1 (https=) |
| AU (1) | AU2010322478B2 (https=) |
| BR (1) | BR112012011518B8 (https=) |
| CA (1) | CA2777746C (https=) |
| ES (1) | ES2442797T3 (https=) |
| IN (1) | IN2012DN03391A (https=) |
| MX (1) | MX2012005329A (https=) |
| RU (1) | RU2542582C2 (https=) |
| TW (1) | TW201121957A (https=) |
| UY (1) | UY33037A (https=) |
| WO (1) | WO2011062550A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158117A1 (en) * | 2011-05-17 | 2012-11-22 | Astrazeneca Ab | Combination therapies for treating pain |
| US9598409B2 (en) * | 2013-01-31 | 2017-03-21 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| CN105992761A (zh) * | 2013-12-20 | 2016-10-05 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法 |
| US10195198B2 (en) | 2014-07-03 | 2019-02-05 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| WO2020135771A1 (zh) * | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| JP2023513373A (ja) * | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | Ｐ２ｘ３修飾薬 |
| EP4198034A4 (en) * | 2020-08-13 | 2024-01-17 | Tuojie Biotech (Shanghai) Co., Ltd. | BENZIMIDAZOLE DERIVATIVES, PRODUCTION PROCESS THEREOF AND MEDICAL USE THEREOF |
| TW202227458A (zh) * | 2020-12-04 | 2022-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含有稠合三環的化合物及其醫藥用途 |
| CN114478508A (zh) * | 2021-12-31 | 2022-05-13 | 淮北师范大学 | 一种苯并咪唑化合物的结晶形式 |
| WO2023151658A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 一种p2x3受体拮抗剂的可药用盐及其制备方法 |
| WO2023151660A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 一种p2x3受体拮抗剂的结晶形式及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6026A (en) * | 1849-01-09 | Cast-iron car-wheel | ||
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| CN100415723C (zh) * | 2000-01-17 | 2008-09-03 | 帝人株式会社 | 苯并咪唑衍生物 |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| MX2007003105A (es) * | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| CN101674827A (zh) * | 2007-03-02 | 2010-03-17 | 先灵公司 | 苯并咪唑衍生物及其使用方法 |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| CA2703909A1 (en) * | 2007-10-31 | 2009-05-07 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
-
2010
- 2010-11-17 BR BR112012011518A patent/BR112012011518B8/pt active IP Right Grant
- 2010-11-17 CA CA2777746A patent/CA2777746C/en active Active
- 2010-11-17 MX MX2012005329A patent/MX2012005329A/es active IP Right Grant
- 2010-11-17 IN IN3391DEN2012 patent/IN2012DN03391A/en unknown
- 2010-11-17 WO PCT/SE2010/051269 patent/WO2011062550A1/en not_active Ceased
- 2010-11-17 EP EP10831876.7A patent/EP2501697B1/en active Active
- 2010-11-17 KR KR1020127012726A patent/KR20120113709A/ko not_active Withdrawn
- 2010-11-17 AU AU2010322478A patent/AU2010322478B2/en active Active
- 2010-11-17 CN CN201080061596.6A patent/CN102741245B/zh active Active
- 2010-11-17 TW TW099139607A patent/TW201121957A/zh unknown
- 2010-11-17 JP JP2012539853A patent/JP5657018B2/ja active Active
- 2010-11-17 ES ES10831876.7T patent/ES2442797T3/es active Active
- 2010-11-17 AR ARP100104240A patent/AR079050A1/es unknown
- 2010-11-17 RU RU2012124268/04A patent/RU2542582C2/ru active
- 2010-11-18 UY UY0001033037A patent/UY33037A/es not_active Application Discontinuation
-
2012
- 2012-05-16 US US13/472,825 patent/US8530467B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2442797T3 (es) | 2014-02-13 |
| EP2501697A4 (en) | 2013-04-24 |
| EP2501697A1 (en) | 2012-09-26 |
| UY33037A (es) | 2011-06-30 |
| CN102741245B (zh) | 2014-11-05 |
| EP2501697B1 (en) | 2013-10-23 |
| RU2012124268A (ru) | 2013-12-27 |
| AU2010322478B2 (en) | 2013-11-14 |
| CA2777746C (en) | 2019-05-14 |
| RU2542582C2 (ru) | 2015-02-20 |
| US20120289504A1 (en) | 2012-11-15 |
| BR112012011518B1 (pt) | 2020-03-10 |
| CN102741245A (zh) | 2012-10-17 |
| MX2012005329A (es) | 2012-05-29 |
| IN2012DN03391A (https=) | 2015-10-23 |
| WO2011062550A1 (en) | 2011-05-26 |
| JP5657018B2 (ja) | 2015-01-21 |
| BR112012011518A2 (pt) | 2016-06-28 |
| US8530467B2 (en) | 2013-09-10 |
| KR20120113709A (ko) | 2012-10-15 |
| AU2010322478A1 (en) | 2012-05-31 |
| CA2777746A1 (en) | 2011-05-26 |
| BR112012011518B8 (pt) | 2023-01-10 |
| JP2013511517A (ja) | 2013-04-04 |
| TW201121957A (en) | 2011-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| UY33547A (es) | COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| SV2011003903A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| UY32062A (es) | Inhibidores de beta-secretasa | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| UY33480A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento. | |
| ECSP10010693A (es) | Compuestos pirazólicos 436 | |
| CR10479A (es) | Modulares bencimidazolicos de vr1 | |
| UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
| CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| CO6761373A2 (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| GT200600117A (es) | Nuevos compuestos farmaceuticos | |
| AR090806A1 (es) | Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |